Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Femdophilus
- Development stage
- Phase 1
- Lead developer
- Jarrow Formulas
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Intravesical, Vaginal
01
Overview
Femdophilus is a probiotic biological agent composed of two specific, clinically documented strains: *Lactobacillus rhamnosus* (GR-1) and *Lactobacillus reuteri* (RC-14). Originally discovered and developed by Dr. Gregor Reid and Dr. Andrew Bruce at Urex Biotech and manufactured by CHR-Hansen, it is traditionally marketed as an oral dietary supplement to support vaginal and urinary tract health in women. The mechanism of action involves the competitive exclusion of uropathogens and the restoration of healthy microbial flora. In clinical research, specifically a Phase 1 trial sponsored by the Lahey Clinic (NCT04077749), the product is being evaluated for intravesical instillation—where the capsule contents are dissolved in saline and delivered directly into the bladder—to prevent catheter-associated urinary tract infections (UTIs) in patients with chronic indwelling catheters.
- Brand names
- Fem-dophilusFemdophilus
- Other names
- GR-1/RC-14Lactobacillus rhamnosus GR-1Lactobacillus reuteri RC-14
02
Targets
Vaginal and lower urinary tract microbiomeVaginal pH and local metabolite environment
Beyond the preview
Go deeper on Femdophilus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Femdophilus.